Qarziba 20mg (Dinutuximab Vials) 20mg/4.5ml

Qarziba 20mg (Dinutuximab) is an immunotherapy medication used in cancer treatment. This vial form contains 20mg per 4.5ml for infusion therapy. Find Qarziba 20mg online for targeted pediatric cancer support.

Strength

20mg/4.5ml

Pack Size

Storage

Ambient

Manufacturer / TM Owner

HSP

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Qarziba 20mg (Dinutuximab) is used in combination with other therapies for high-risk neuroblastoma in pediatric patients. It targets specific antigens on cancer cells to help the immune system recognize and attack tumors. This medication is typically administered in clinical settings as part of a broader treatment protocol.

Side Effects

Qarziba 20mg may cause infusion-related reactions such as fever, low blood pressure, or breathing difficulties during administration. Some patients experience pain, redness, or swelling at the infusion site. These effects are monitored closely by healthcare professionals during treatment.

Precautions & Warnings

Qarziba 20mg should only be handled and administered by trained medical professionals in a controlled environment. Patients should be monitored for signs of allergic reactions or infusion-related complications. Keep the vial at room temperature and protect from light until use.

Avoid Interactions

Qarziba 20mg may interact with medications that suppress the immune system, such as corticosteroids or chemotherapy. Avoid live vaccines during treatment due to potential reduced effectiveness. Inform your healthcare provider about all medications and supplements being used.

Frequently Asked Questions

Qarziba 20mg is used to treat high-risk neuroblastoma in pediatric patients as part of combination therapy.

It is given as an intravenous infusion in a clinical setting under medical supervision.

Common effects include fever, infusion reactions, and pain at the injection site.

It may interact with immune-suppressing drugs; consult your doctor before combining treatments.

Qarziba 20mg is available through licensed pharmacies and medical suppliers with a prescription.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.